NRx Pharma receives Nasdaq MVLS deficiency notice; must regain compliance by Feb 3, 2025

NRX Pharmaceuticals, Inc.

Nasdaq notified NRx on Aug 6 that MVLS was below $35M minimum from June 14 to Aug 5, 2024.
Company has 180 days (until Feb 3, 2025) to achieve MVLS >= $35M for 10 consecutive days.
Failure to regain compliance may result in delisting; Company can appeal but no assurance of success.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.